Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER

The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 inhibition in Subjects with Elevated Risk) trial was conducted to study cardiovascular outcomes of treatment with evolocumab. The trial was terminated after a median follow-up of 2.2 years instead of the planned 3.6 years. We question...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bruggen, Folkert H., Luijendijk, Hendrika J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748321/
https://www.ncbi.nlm.nih.gov/pubmed/34008143
http://dx.doi.org/10.1007/s40256-021-00480-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748321/
https://www.ncbi.nlm.nih.gov/pubmed/34008143
http://dx.doi.org/10.1007/s40256-021-00480-y

Ejemplares similares